Evommune, Inc. EVMN
Evommune, Inc. (NYSE: EVMN) is an immunology/inflammation drug developer. Its lead program, EVO756, is in Phase 2 for Moderate-to-severe atopic dermatitis. Its next catalyst on record is EVO301: Phase 2b commencement (Q2 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: EVO301 — Phase 2b commencement (Q2 2027). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| EVO756 (oral MRGPRX2 antagonist) - atopic dermatitis Phase 2b | Atopic dermatitis | small molecule | Phase 2 |
| EVO756 - migraine prophylaxis Phase 2b | Refractory migraine | small molecule | Phase 2 |
| EVO756 - chronic spontaneous urticaria | CSU | small molecule | Phase 2 |
| EVO301 (IL-18 binding protein, licensed from AprilBio) | Inflammatory disease (ulcerative colitis among initial focus areas) | protein/peptide | Phase 1 |
Recent results and decisions
- Aug 6, 2026started Global Phase 2b dose-ranging migraine prophylaxis trial (~330 patients) initiated July 2026; top-line data expected 2027.
In July 2026, the Company initiated a global randomized, double-blind, placebo-controlled Phase 2b dose-ranging clinical trial in migraine prophylaxis.
Filing - Jun 29, 2026missed Phase 2b (n=160) did not meet primary endpoint of mean UAS7 change at week 12 at any dose; company says results do not support further CSU development.
The study did not meet the primary endpoint of mean change in a patient’s Urticaria Activity Score over seven days (UAS7) at 12 weeks at any dose.
Filing - Feb 10, 2026met Phase 2a (n=70) met primary EASI endpoint: 33% placebo-adjusted EASI improvement at week 12, 23% vIGA 0/1 vs 0% placebo, no related serious AEs.
today announced positive top-line results from its randomized, double-blind, placebo-controlled Phase 2a trial evaluating EVO301.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.